First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. (Q38397851)
Jump to navigation
Jump to search
scientific article published on 30 December 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. |
scientific article published on 30 December 2015 |
Statements
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study (English)
Keunchil Park
Sang-We Kim
Meng-Chih Lin
Virote Sriuranpong
Chun-Ming Tsai
Jong-Seok Lee
Jin-Hyoung Kang
K C Allen Chan
Pablo Perez-Moreno
Peter Button